125 I Radioactive Particles Drive Protective Autophagy in Hepatocellular Carcinoma by Upregulating ATG9B

I radioactive particles implantation have demonstrated efficacy in eradicating hepatocellular carcinoma (HCC). However, progressive resistance of HCC to I radioactive particles has limited its wide clinical application. We investigated the cellular responses to I radioactive particles treatment and...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical and translational hepatology Vol. 11; no. 2; p. 360
Main Authors Xiao, Yunhua, Yuan, Jing, Yang, Chongshuang, Xiong, Junru, Deng, Liangyu, Liang, Qinghua, He, Chuang, Li, Liangshan, He, Fengtian, Huang, Xuequan
Format Journal Article
LanguageEnglish
Published United States 28.04.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:I radioactive particles implantation have demonstrated efficacy in eradicating hepatocellular carcinoma (HCC). However, progressive resistance of HCC to I radioactive particles has limited its wide clinical application. We investigated the cellular responses to I radioactive particles treatment and autophagy-related 9B (ATG9B) silencing in HCC cell lines and Hep3B xenografted tumor model using Cell Counting Kit-8 reagent, western blotting, immunofluorescence, flow cytometry, transmission electron microscopy and immunohistochemistry. In this study, we demonstrated that I radioactive particles induced cell apoptosis and protective autophagy of HCC and . Inhibition of autophagy enhanced the radiosensitivity of HCC to I radioactive particles. Moreover, I radioactive particles induced autophagy by upregulating ATG9B, with increased expression level of LC3B and decreased expression level of p62. Furthermore, ATG9B silencing downregulated LC3B expression and upregulated p62 expression and enhanced radiosensitivity of HCC to I radioactive particles and . Inhibition of ATG9B enhanced the antitumor effects of I particle radiation against HCC and Our findings suggest that I particle radiation plus chloroquine or/and the ATG9B inhibitor may be a novel therapeutic strategy for HCC.
ISSN:2310-8819